Health outcomes associated with antihypertensive therapies used as first-line agents: A systematic review and meta-analysis

JAMA

Volumn 277, Issue 9, 1997, Pages 739-745

  Psaty, Bruce M ^a,b   Smith, Nicholas L ^b   Siscovick, David S ^a,b   Koepsell, Thomas D ^a,b   Weiss, Noel S ^b   Heckbert, Susan R ^b   Lemaitre, Rozenn N ^b   Wagner, Edward H ^b,c   Furberg, Curt D ^d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE; NIFEDIPINE; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; REVIEW; STROKE; TREATMENT OUTCOME;

EID: 0031044480     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.9.739     Document Type: Review

References (89)

1. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
2. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1988 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC IV). Arch Intern Med. 1988;148: 1023-1038.
3. Tobian L, Brunner HR, Cohn JN, et al. Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V consensus guidelines. Am J Hypertens. 1994;7:859-872.
4. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologie management of hypertension in the United States. Arch Intern Med. 1995;155:829-837.
5. Psaty BM, Siscovick DS, Weiss NS, et al. Hypertension and outcomes research: from clinical trials to clinical epidemiology. Am J Hypertens. 1996; 9:178-183.
6. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125:605-613.
7. MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled triais. Prog Cardiovasc Dis. 1986;29(suppl 1):99-118.
8. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, 2: short-term reductions in blood pressure: overview of randomized drug trials in their epidemiologic context. Lancet. 1990;335:827-838.
9. Mulrow CD, Cornell JA, Herrera CR, Kadri A, Farnett L, Aguilar C. Hypertension in the elderly: implications and generalizability of randomized trials. JAMA. 1994;272:1932-1938.
10. Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 1993; 153:578-581.
11. Cutler JA, Psaty BM, MacMahon S, Furberg CD. Public health issues in hypertension control: what has been learned from clinical trials. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. 2nd ed. New York, NY: Raven Press; 1995:253-279.
12. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA. 1982;248:1465-1477.
13. Miettinen TA, Huttunen JK, Naukkarinen V, et al. Multifactorial primary prevention of cardiovascular diseases in middle-aged men: risk factor changes, incidence and mortality. JAMA. 1985;254: 2097-2102.
14. Wolff FW, Lindeman RD. Effects of treatment in hypertension: results of a controlled study. J Chronic Dis. 1966;19:227-240.
15. Sprackling ME, Mitchell JRA, Short AH, Watt G. Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ. 1981; 283:1151-1153.
16. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens. 1985;3:379-392.
17. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 1987;5:561-572.
18. Perry HM Jr, Goldman AI, Lavin MA, et al, for the Veterans Administration-National Heart, Lung, and Blood Institute Group for Evaluating Treatment in Mild Hypertension. Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility study. Ann N Y Acad Sci. 1978;304:267-288.
19. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202:116-122.
20. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment, II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213:1143-1152.
21. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program, I: reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979; 242:2562-2571.
22. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program, III: reduction in stroke incidence among persons with high blood pressure. JAMA. 1982;247:633-638.
23. Hypertension Detection and Follow-up Program Cooperative Group. Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris: 5-year findings of the Hypertension Detection and Follow-up Program. Hypertension. 1984;6(suppl 1):I198-I206.
24. Hegeland A. Treatment of mild hypertension: a five year controlled drug trial, the Oslo Study. Am J Med. 1980;69:725-732.
25. The Management Committee of the Australian National Blood Pressure Study. The Australian therapeutic trial in mild hypertension. Lancet. 1980; 1:1262-1267.
26. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ. 1985;291:97-104.
27. Smith WM, for the US Public Health Service Hospitals Cooperative Study Group. Treatment of mild hypertension: results of a ten-year intervention trial. Hypertension. 1977;25(suppl 1):I98-I105.
28. Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA. 1974;229:409-418.
29. Barraclough M, Joy MD, MacGregor GA, et al. Control of moderately raised blood pressure: report of a co-operative randomized controlled trial. BMJ. 1973;3:434-436.
30. Kuramoto K, Matsushita S, Kuwajima I, Murakami M. Prospective study on the treatment of mild hypertension in the aged. Jpn Heart J. 1981;22:75-85.
31. Carter AB. Hypotensive therapy in stroke survivors. Lancet. 1970;1:485-489.
32. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity from the European Working Party on high blood pressure in the elderly trial. Lancet. 1985;1:1350-1354.
33. Perry MH Jr, Smith WM, McDonald RH, et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study. Stroke. 1989;20:4-13.
34. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264.
35. Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992; 304:405-412.
36. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ. 1986;243:1145-1151.
37. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP-Hypertension). Lancet. 1991;338: 1281-1285.
38. Sewester CS, Dombek CE, Olin BR, Scott JA, Hebel SK, Novak KK, eds. Drug Facts and Comparisons. 1996 ed. St Louis, Mo: Facts and Comparisons; 1996.
39. Ekbom T, Dahlof B, Hansson L, Lindholm SH, Schersten B, Wester PO. Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study. J Hypertens. 1992;10: 1525-1530.
40. Rothman KJ. Modern Epidemiology. Boston, Mass: Little Brown & Co Inc; 1986.
41. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med. 1989;8: 141-151.
42. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease, 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
43. Psaty BM, Koepsell TD, Manolio TA, et al. Risk ratios and risk differences in estimating the effect of risk factors for cardiovascular disease in the elderly. J Clin Epidemiol. 1990;43:961-970.
44. Chatellier G, Zapletal E, Lemitre D, Menard J, Degoulet P. The number needed to treat: a clinically useful nomogram in its proper context. BMJ. 1996;312:426-429.
45. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA. 1996;275:1507-1513.
46. Neaton JD, Grimm RH Jr, Prineas RJ, et al, for the Treatment of Mild Hypertension Research Group. Treatment of Mild Hypertension Study (TOMHS): final results. JAMA. 1993;270:713-724.
47. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six anti-hypertensive agents with placebo. N Engl J Med. 1993;328:914-921.
48. Grimm RH Jr, Flack JM, Grandits GA, et al, for the Treatment of Mild Hypertension Study (TOMHS) Research Group. Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA. 1996;275:1549-1556.
49. Kasiske BL, Ma JZ, Kalil RSN, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med. 1995;122:133-141.
50. Black HR. Treatment of mild hypertension: the more things change. JAMA 1993;270:757-759.
51. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA 1996;276:785-791.
52. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al. Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet. 1990;335:1109-1113.
53. The HINT Research Group. Early treatment of unstable angina in the coronary care unit: a randomised, double-blind, placebo-controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br Heart J. 1986; 56:400-413.
54. Goldbourt R, Behar S, Reicher-Reiss H, Zion M, Mandelzweig L, Kaplinsky E, for the SPRINT Study Group. Early administration of nifedipine in suspected acute myocardial infarction: the Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med. 1993;153:345-353.
55. Furberg CD, Psaty BM, Myers JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1331. Correction: Circulation. 1996;93:1475-1476.
56. Thadani U, Sellner SR, Glasser S, et al. Double-bund, dose-response, placebo-controlled multicenter study of nisoldipine: a new second-generation calcium channel blocker in angina pectoris. Circulation. 1991;84:2398-2408.
57. Scheidt S, LeWinter MM, Hermanovich J, Venkataraman K, Freedman D. Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial. Am J Cardiol. 1986; 58:715-721.
58. Gheorghiade M, Weiner DA, Chakko S, Lessem JN, Klein MD. Monotherapy of stable angina with nicardipine hydrochloride: double-blind, placebo-controlled, randomized study. Eur Heart J. 1989; 10:695-701.
59. Waters D, Cravan TE, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation. 1993;87:1067-1075.
60. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol. 1991;67:1295-1297.
61. Held PH, Yusuf S. Calcium antagonists in the treatment of ischemic heart disease: myocardial infarction. Coron Artery Dis. 1994;5:21-26.
62. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H, on behalf of the CONSENSUS II Study Group. Effects of administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327:678-684.
63. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450-1456.
64. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA. 1994; 271:275-279.
65. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939-945.
66. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. Beta-blockers and sudden cardiac death. Ann Intern Med. 1995;123:358-367.
67. Ryan TJ, Anderson JL, Antman EM, et al. ACC/ AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute MI). J Am Coll Cardiol. 1996;28:1328-1428.
68. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
69. Kaplan NM, Gifford RW Jr. Choice of initial therapy for hypertension. JAMA 1996;275:1577-1580.
70. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 1994;330: 1852-1857.
71. Hoes AW, Grobbee DE, Lubsen J, Man in 't Veld AJ, van der Does E, Hofman A. Diuretics, beta-blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med. 1995; 123:481-487.
72. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274: 620-625.
73. Aursnes I, Litleskare I, Froyland H, Abdelnoor M. Association between various drugs used for hypertension and risk of acute myocardial infarction. Blood Press. 1995;4:157-163.
74. Jick H, Derby LE, Guewich V, Vasilakis C. The risk of myocardial infarction associated with antihypertensive drug treatment in persons with uncomplicated essential hypertension. Pharmacotherapy. 1996;16:321-326.
75. Pahor M, Guralnik JM, Corti MC, Foley JD, Carbonin P, Havlik RJ. Long-term survival and use of antihypertensive medication in older persons. J Am Geriatr Soc. 1995;43:1191-1197.
76. Fallowfield JM, Blenkinsopp J, Raza A, Fowkes AG, Higgins TJ, Bridgman KM. Post-marketing surveillance of lisinopril in general practice in the UK. Br J Clin Pract. 1993;47:296-304.
77. Casiglia E, Spolaore P, Mazza A, et al. Effect of two different therapeutic approaches on total and cardiovascular mortality in a Cardiovascular Study in the Elderly (CASTEL). Jpn Heart J. 1994;35: 589-600.
78. Gong L, Zwang W, Zhu Y, et al. Shanghai Trial of Nifedipine in the Elderly (STONE) Study. J Hypertens. 1996;14:1237-1246.
79. Study Group on Long-term Antihypertensive Therapy. A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension - the GLANT Study. Hypertens Res. 1995;18:235-244.
80. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. 3rd ed. St Louis, Mo: Mosby-Year Book Inc; 1996.
81. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273: 408-412.
82. National Heart, Lung, and Blood Institute. New Analyses Regarding the Safety of Calcium-Channel Blockers: A Statement for Health Professionals From the National Heart, Lung and Blood Institute. Bethesda, Md: National Institutes of Health; September 1995.
83. Pahor M, Guralnik JM, Furberg CD, Carbonin P, Havlik RJ. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet. 1996;347:1061-1065.
84. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens. 1996;9:695-699.
85. Pahor M, Guralnik JM, Ferrucci L, et al. Calcium channel blockers and incidence of cancer in aged populations. Lancet. 1996;348:493-497.
86. Epstein M. Calcium antagonists should continue to be used as first-line treatment of hypertension. Arch Intern Med. 1995;155:2150-2156.
87. Lindqvist M, Kahan T, Melcher A, Hjemdahl P. Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension. Hypertension. 1994;24:287-296.
88. Davis BR, Cutler JA, Gordon DJ, et al, for the ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342-360.
89. Slovick DK, Amery A, Birkenhager W, et al. SYST-EUR multicentre trial on the treatment of isolated systolic hypertension in the elderly: first interim report. J Hum Hypertens. 1993;7:201-203.